CN118354769A - 治疗激越和其它痴呆症相关的行为症状的方法 - Google Patents

治疗激越和其它痴呆症相关的行为症状的方法 Download PDF

Info

Publication number
CN118354769A
CN118354769A CN202280078331.XA CN202280078331A CN118354769A CN 118354769 A CN118354769 A CN 118354769A CN 202280078331 A CN202280078331 A CN 202280078331A CN 118354769 A CN118354769 A CN 118354769A
Authority
CN
China
Prior art keywords
fasudil
patient
dementia
treatment
shock
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280078331.XA
Other languages
English (en)
Chinese (zh)
Inventor
T·麦卡利斯特
S·雅各布森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuerxi Pharmaceutical Co ltd
Original Assignee
Wuerxi Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuerxi Pharmaceutical Co ltd filed Critical Wuerxi Pharmaceutical Co ltd
Publication of CN118354769A publication Critical patent/CN118354769A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280078331.XA 2021-11-29 2022-11-15 治疗激越和其它痴呆症相关的行为症状的方法 Pending CN118354769A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163283696P 2021-11-29 2021-11-29
US63/283,696 2021-11-29
PCT/US2022/079861 WO2023097151A1 (en) 2021-11-29 2022-11-15 Methods of treating agitation and other dementia-associated behavioral symptoms

Publications (1)

Publication Number Publication Date
CN118354769A true CN118354769A (zh) 2024-07-16

Family

ID=86540411

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280078331.XA Pending CN118354769A (zh) 2021-11-29 2022-11-15 治疗激越和其它痴呆症相关的行为症状的方法

Country Status (7)

Country Link
US (2) US20240423998A1 (https=)
EP (1) EP4440566A4 (https=)
JP (1) JP2024544500A (https=)
CN (1) CN118354769A (https=)
CA (1) CA3236462A1 (https=)
MX (1) MX2024006505A (https=)
WO (1) WO2023097151A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021216139A1 (en) * 2020-04-23 2021-10-28 Woolsey Pharmaceuticals, Inc Methods of using rho kinase inhibitors to treat alzheimer's disease
WO2025024104A2 (en) * 2023-07-06 2025-01-30 Woolsey Pharmaceuticals, Inc. Method for reducing caregiver burden associated with alzheimer's disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104340D0 (sv) * 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
WO2008019395A2 (en) 2006-08-10 2008-02-14 Translational Genomics Research Institute Compounds for improving learning and memory
US20080044390A1 (en) 2006-08-11 2008-02-21 Xiaowei Jin Methods and compositions for the treatment of neurodegenerative disorders
CN101612157A (zh) 2008-06-26 2009-12-30 天津红日药业股份有限公司 法舒地尔诱导成年脑内源性神经干细胞再生的用途
US9980972B2 (en) 2012-03-12 2018-05-29 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Rho kinase inhibitors for use in treating familial amyotrophic lateral sclerosis
WO2015070170A1 (en) * 2013-11-08 2015-05-14 The Translational Genomics Research Institute Compounds for cognitive enhancement and methods of use thereof
US10537567B2 (en) * 2017-07-11 2020-01-21 BioAxone BioSciences, Inc. Kinase inhibitors for treatment of disease
WO2019018855A1 (en) * 2017-07-21 2019-01-24 Kadmon Corporation, Llc ALPHA PROPELLER PROTEIN KINASE INHIBITORS ("COILED-COIL") ASSOCIATED WITH RHO
EP3868408A4 (en) 2018-10-15 2022-07-06 National University Corporation Tokai National Higher Education and Research System Antipsychotic and use thereof
MX2022008513A (es) * 2020-01-09 2022-08-08 Woolsey Pharmaceuticals Inc Metodos para tratar la deambulacion asociada con la demencia cortical.
US11642352B2 (en) 2020-03-25 2023-05-09 Woolsey Pharmaceuticals, Inc. Methods of treating wandering in Lewy dody dementia
CA3169944A1 (en) 2020-03-25 2021-09-30 Thomas Macallister Methods of using rho kinase inhibitors to treat frontotemporal dementia
WO2021216139A1 (en) * 2020-04-23 2021-10-28 Woolsey Pharmaceuticals, Inc Methods of using rho kinase inhibitors to treat alzheimer's disease
CN116249532A (zh) 2020-06-15 2023-06-09 乌尔塞制药公司 使用Rho激酶抑制剂治疗血管性痴呆的方法
MX2022016336A (es) 2020-06-25 2023-01-24 Woolsey Pharmaceuticals Inc Metodos de tratamiento de trastornos del neurodesarrollo.
MX2023000600A (es) 2020-07-14 2023-02-13 Woolsey Pharmaceuticals Inc Metodos de tratamiento de proteinopatias.
EP4232041A4 (en) 2020-10-22 2024-09-25 Woolsey Pharmaceuticals, Inc. Methods of treating 4-repeat tauopathies
US20220331333A1 (en) 2021-04-16 2022-10-20 Universite De Strasbourg Rhoa pathway inhibitor in the treatment of neurodevelopmental disorder or neuropsychiatric disorder
WO2022245708A1 (en) 2021-05-19 2022-11-24 Woolsey Pharmaceuticals, Inc. Methods of treating depression and anxiety
MX2023013538A (es) 2021-05-19 2023-11-27 Woolsey Pharmaceuticals Inc Metodos para tratar la depresion y la ansiedad.

Also Published As

Publication number Publication date
JP2024544500A (ja) 2024-12-03
WO2023097151A1 (en) 2023-06-01
US20230201219A1 (en) 2023-06-29
MX2024006505A (es) 2024-06-05
US20240423998A1 (en) 2024-12-26
CA3236462A1 (en) 2023-06-01
EP4440566A1 (en) 2024-10-09
US11865119B2 (en) 2024-01-09
EP4440566A4 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
Ahmed et al. Cannabinoids in late‐onset Alzheimer's disease
US9211288B2 (en) Compositions comprising vortioxetine and donepezil
US11865119B2 (en) Methods of treating agitation and other dementia-associated behavioral symptoms
HUP0201275A2 (en) Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts and pharmaceutical composition containing the compound
US11311553B1 (en) Methods of treating 4-repeat tauopathies
US20230285409A1 (en) Methods of using rho kinase inhibitors to treat vascular dementia
CN115103672A (zh) 治疗与皮质性痴呆相关的游荡的方法
KR101994596B1 (ko) 신경정신계 장애의 치료를 위한 조성물 및 방법
JP2016514688A5 (https=)
CA3175183A1 (en) Methods of using rho kinase inhibitors to treat alzheimer's disease
US20060241144A1 (en) Method for treating apathy syndrome
JPWO2018221728A1 (ja) アルツハイマー型認知症予防または治療剤
EP4103187B1 (en) Fasudil for treating pseudobulbar affect
JP2025087929A (ja) うつ病および／またはうつ状態の治療および／または予防用医薬
JP2025531623A (ja) タシピミジンおよびｃｙｐ２ｄ６阻害薬の併用療法
VanDenBerg Clinically significant interactions with cholinesterase inhibitors and other antidementia agents
CN101815517A (zh) 神经细胞死亡抑制剂
Dodd et al. Duloxetine for major depression
BR112021012491A2 (pt) Combinações antineurodegenerativas de domperidona e uso
Pacific et al. Seizures associated with memantine use.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination